Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Cassava Sciences Inc
(NQ:
SAVA
)
29.00
-0.58 (-1.96%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Cassava Sciences Inc
< Previous
1
2
...
14
15
16
17
18
19
20
21
Next >
12 Health Care Stocks Moving In Wednesday's Intraday Session
August 25, 2021
Gainers Regencell Bioscience (NASDAQ:RGC) stock rose 100.19% to $30.63 during Wednesday's regular session. Regencell Bioscience's stock is trading at a volume of 8...
Via
Benzinga
Mid-Day Market Update: Gold Down 1%; Locust Walk Acquisition Shares Jump
August 25, 2021
Midway through trading Wednesday, the Dow traded up 0.20% to 35,435.82 while the NASDAQ rose 0.05% to 15,027.49. The S&P also rose, gaining 0.14% to 4,492.54. The U.S. has the...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
36 Stocks Moving In Wednesday's Mid-Day Session
August 25, 2021
Gainers Locust Walk Acquisition Corp. (NASDAQ: LWAC) shares jumped 188% to $25.34 after the company announced stockholders approved a business combination with eFFECTOR...
Via
Benzinga
Here's Why Cassava Sciences Is Having a Bad Day
August 25, 2021
The FDA received a citizen petition requesting a halt to clinical trials with the company's Alzheimer's disease candidate.
Via
The Motley Fool
Exposures
Product Safety
Mid-Morning Market Update: Markets Edge Higher; Dick's Sporting Goods Beats Q2 Views
August 25, 2021
Following the market opening Wednesday, the Dow traded up 0.07% to 35,389.32 while the NASDAQ rose 0.17% to 15,045.45. The S&P also rose, gaining 0.14% to 4,492.57. The U.S....
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Cassava Sciences Stock Shows Promise With Simufilam Trials Drawing Near
August 25, 2021
SAVA stock is up as the company announced the FDA has agreed on study protocols for Phase 3 clinical trials of Simufilam.
Via
InvestorPlace
Exposures
Product Safety
Cassava Stock Plummets On Claims Of 'Data Manipulation' In Alzheimer's Testing
August 25, 2021
A shareholder firm called for the FDA to halt Cassava Sciences' studies in Alzheimer's disease, leading SAVA stock to plummet Wednesday.
Via
Investor's Business Daily
Exposures
Product Safety
Cassava Sciences Shares Sink With Alzheimer's Drug Mired In Controversy
August 25, 2021
Neurodegenerative diseases-focused biopharma Cassava Sciences, Inc. (NASDAQ: SAVA) saw both sides of the world Tuesday. The stock rallied to close higher by 2% after it announced...
Via
Benzinga
Why Cassava Sciences' Stock Is Getting Hammered Today
August 25, 2021
Cassava Sciences, Inc. (NASDAQ: SAVA) shares are trading lower on negative claims that were posted online yesterday after market hours. The company issued a response to the claims...
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
August 25, 2021
Gainers Regencell Bioscience (NASDAQ:RGC) stock increased by 25.49% to $19.2 during Wednesday's pre-market session. The company's market cap stands at $242.7...
Via
Benzinga
The Daily Biotech Pulse: Lilly Strikes $1.6B R&D Collaboration, FSD Pulls Plug On COVID-19 Program, Cassava Sinks On Questions About Alzheimer's Drug
August 25, 2021
ere's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 24) Agenus Inc. (NASDAQ: AGEN)...
Via
Benzinga
Exposures
COVID-19
21 Stocks Moving in Wednesday's Pre-Market Session
August 25, 2021
Gainers Regencell Bioscience Holdings Limited (NASDAQ: RGC) rose 40.1% to $21.43 in pre-market trading after gaining over 11% on Tuesday. Regencell Bioscience recently reported...
Via
Benzinga
Cassava Sciences Has an Admirable Goal at Too High a Price
August 24, 2021
It would be great if Cassava Sciences' treatment for Alzheimer's disease worked, but should you pay the high price for SAVA stock? No.
Via
InvestorPlace
Cassava Sciences Receives FDA's Special Protocol Assessment For Alzheimer's Trials
August 24, 2021
Cassava Sciences Inc (NASDAQ: SAVA) announced an agreement with the FDA under a Special Protocol Assessment (SPA) for both of its pivotal Phase 3 trials for oral...
Via
Benzinga
Exposures
Product Safety
Soaring Cassava Sciences Stock Shows Unfettered Promise for Growth
August 20, 2021
With more than 6 million people in the U.S. suffering from Alzheimer's disease, SAVA stock has enormous potential for future profits.
Via
InvestorPlace
Tread Carefully Before Pulling the Trigger on Cassava Sciences
August 20, 2021
While SAVA stock is intriguing based on the underlying Alzheimer’s treatment proposal, this market has an extremely high failure rate.
Via
InvestorPlace
Cassava Sciences Stock Has Had an Epic Run, but Getting in Now Is a Serious Risk
August 19, 2021
SAVA stock has gone "to the moon" thanks to its Alzheimer treatment catalyst, but don't assume it's immune to a possible reversal.
Via
InvestorPlace
These Are the Top Reasons You Should Load Up on Cassava Sciences Stock
August 18, 2021
At the moment, there’s no cure for Alzheimer’s, but Cassava Sciences is working to wipe it out for good, making SAVA stock a buy here.
Via
InvestorPlace
With This Exciting Alzheimer’s Treatment, Cassava Sciences Stock Has Legs
August 16, 2021
Incredible Alzheimer's data suggests that Cassava has the right approach to tackling the disease powering SAVA stock.
Via
InvestorPlace
Cassaca Sciences Stock Is a Buy on the Strength of a Promising Alzheimer’s Drug
August 16, 2021
Skeptics are wrong about Cassava's Alzheimer's drug, as the drug's data is superb. Long-term investors should buy SAVA stock.
Via
InvestorPlace
Why Might Cassava Succeed With Its Alzheimer's Drug, When So Many Have Failed?
August 14, 2021
Alzheimer's research has been hampered by apparently mistaken ideas about what causes the disease. Cassava has a new theory about what's responsible -- and its drug is showing positive results.
Via
The Motley Fool
Why Is Biogen Pursuing a New Direction in Alzheimer's Research?
August 13, 2021
It might be that Biogen, too, is abandoning the theory that amyloid plaque is the cause of the disease.
Via
The Motley Fool
How Much Should An Alzheimer's Drug Cost?
August 13, 2021
The answer is more complicated than you think.
Via
The Motley Fool
Navigating A Speculative Bubble
August 13, 2021
Invest while it inflates; protect before it pops.
Via
Talk Markets
Analyzing the Potential Risks of Cassava Sciences
August 13, 2021
Cassava Sciences has a promising drug candidate for Alzheimer's. However, SAVA stock may be overpriced based on the limited data so far.
Via
InvestorPlace
Why Is Cassava Sciences' Stock So Volatile?
August 12, 2021
The stock is up 1,700% year to date.
Via
The Motley Fool
Cassava Sciences vs. Biogen
August 12, 2021
Who will emerge victorious in the race to help Alzheimer's patients?
Via
The Motley Fool
Mid-Afternoon Market Update: Dow Drops 50 Points; IEC Electronics Shares Spike Higher
August 12, 2021
Toward the end of trading Thursday, the Dow traded down 0.14% to 35,435.25 while the NASDAQ rose 0.29% to 14,808.42. The S&P also rose, gaining 0.19% to 4,456.37. The U.S. has...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Here's What Investors Should Know About Cassava's Alzheimer's Drug Candidate
August 11, 2021
Cassava believes that a mutating protein, Filamin A, is a major culprit behind Alzheimer's disease. The company's drug, simufilam, aims to fix this mutation and restore its proper form and function.
Via
The Motley Fool
Bring a Neck Brace When Trading Cassava Sciences
August 11, 2021
Cassava is still pre-revenue but SAVA stock has a flock of strong fans. They bought the dip with gumption, which suggests long-term success.
Via
InvestorPlace
< Previous
1
2
...
14
15
16
17
18
19
20
21
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.